Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/1998

01-10-1998 | ORIGINAL ARTICLE

Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors

Authors: Matthew L. Hanley, Gertrude B. Elion, O. Michael Colvin, Paul L. Modrich, Stephen Keir, David J. Adams, Darell D. Bigner, Henry S. Friedman

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/1998

Login to get access
Metadata
Title
Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors
Authors
Matthew L. Hanley
Gertrude B. Elion
O. Michael Colvin
Paul L. Modrich
Stephen Keir
David J. Adams
Darell D. Bigner
Henry S. Friedman
Publication date
01-10-1998
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/1998
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050848

Other articles of this Issue 6/1998

Cancer Chemotherapy and Pharmacology 6/1998 Go to the issue

ORIGINAL ARTICLE

High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically

SHORT COMMUNICATIONS

Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration

ORIGINAL ARTICLE

Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer

ORIGINAL ARTICLE

Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines

ORIGINAL ARTICLE

Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer

ORIGINAL ARTICLE

Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits